AI-ECG Platform vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-ECG Platform

by Carewell Health

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

Tool A offers a comprehensive AI-powered platform for the automatic analysis and diagnosis of various current cardiovascular conditions from 12-lead ECGs. In contrast, Tool B is a specialized AI algorithm designed to predict the risk of new-onset atrial fibrillation within 12 months for a specific elderly patient population. While both leverage AI for ECG analysis, their distinct diagnostic versus predictive focuses and target applications make them adjacent rather than direct competitors.

Choose AI-ECG Platform if…

Choose the AI-ECG Platform if your clinical setting requires rapid, comprehensive AI-powered analysis for a wide range of 12-lead resting ECG interpretations. This tool is ideal for assisting physicians in diagnosing various major cardiovascular diseases, including arrhythmias, myocardial ischemia, and infarction, with high accuracy and hardware independence.

View AI-ECG Platform →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary goal is to proactively identify elderly patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year. This specialized AI algorithm is best suited for risk stratification and supporting earlier intervention in a specific patient population, rather than general diagnostic interpretation.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-ECG Platform	Tempus ECG-AF
Pricing	Unknown	Contact vendor
Deployment	On-premise (AI-ECG Workstation), web-based (Management Portal), and client-based (AI-ECG Diagnostic Client).	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AI-ECG Platform

Tool A offers a more flexible and comprehensive user experience with its web-based portal, dedicated diagnostic client for professional review, and hardware independence. Its ability to support various ECG data formats and provide rapid diagnosis in approximately 3 seconds further enhances its usability.

Clinical Value

AI-ECG Platform

Tool A provides a broader diagnostic scope, assisting physicians in interpreting 12-lead resting ECGs with over 95% accuracy for major cardiovascular diseases including arrhythmias, myocardial ischemia, and infarction. While Tool B offers valuable predictive insights for AF, Tool A's immediate and diverse diagnostic capabilities offer more widespread clinical utility for a broader range of presenting conditions.

Pricing & Value

Tempus ECG-AF

Tool B explicitly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, providing clear financial transparency and a defined pathway for economic value. Tool A, in contrast, only states 'contact for pricing,' offering no public information regarding its cost or potential for reimbursement.

Enterprise Readiness

Tempus ECG-AF

Tool B explicitly confirms HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical requirements for enterprise adoption in healthcare. While Tool A states these are 'likely,' Tool B's explicit confirmation provides a higher level of assurance and regulatory readiness for healthcare organizations.

Innovation

Tempus ECG-AF

While both tools leverage AI for ECG analysis, Tool B demonstrates greater innovation by focusing on predictive risk stratification for new-onset Atrial Fibrillation within 12 months in a specific patient population. This moves beyond traditional diagnostic assistance to proactive identification and earlier intervention, representing a more advanced application of AI in clinical care.

Support & Docs

Tie

Neither the provided structured facts nor general web searches yielded specific details regarding the support channels, documentation quality, or service level agreements for either Tool A or Tool B. Without this information, it is not possible to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-ECG Platform	Tempus ECG-AF
Primary Purpose	AI automatic analysis and diagnosis system for 12-lead resting ECGs, assisting physicians in interpretation.	AI-based algorithm to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Target Patient Population	Not specified	Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
Compatibility	Hardware independent, compatible with most ECG machines; Supports Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, MFER ECG data formats.	Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.
Key Diagnostic Capabilities	Diagnoses arrhythmias, ventricular hypertrophy, myocardial ischemia, and myocardial infarction.	Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months.
Accuracy/Performance Claim	Over 95% accuracy in diagnosing major cardiovascular diseases.	Not specified

Videos

Demos, reviews, and walkthroughs featuring AI-ECG Platform and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of each tool?

The AI-ECG Platform (Tool A) is designed for general 12-lead resting ECG interpretation, assisting physicians in diagnosing major cardiovascular diseases such as arrhythmias, myocardial ischemia, and myocardial infarction. Tempus ECG-AF (Tool B) is an AI-based algorithm focused on identifying patients aged 65 or older at increased risk of developing new-onset atrial fibrillation/flutter within the next 12 months.

How do the target patient populations differ for these tools?

The AI-ECG Platform (Tool A) is intended for general use in interpreting 12-lead resting ECGs across a broad adult patient population. Tempus ECG-AF (Tool B) is specifically for patients aged 65 or older who do not have pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

What are the compatibility requirements for integrating these tools with existing ECG machines?

The AI-ECG Platform (Tool A) is hardware independent and compatible with most ECG machines, supporting various ECG data formats like Carewell ECG, HL7 aECG, DICOM ECG, SCP ECG, and MFER ECG. Tempus ECG-AF (Tool B) is compatible with FDA authorized resting 12-lead ECGs specifically from GE Medical Systems and Philips Medical Systems.

Is there specific information regarding reimbursement for using these AI tools?

Tempus ECG-AF (Tool B) has CMS reimbursement available, with CPT codes 0764T and 0765T to APC 5734, effective January 1, 2025, at a Medicare rate of $128.90. The AI-ECG Platform (Tool A) does not explicitly state reimbursement information in the provided facts.

What are the stated accuracy or performance metrics for each tool?

The AI-ECG Platform (Tool A) claims over 95% accuracy in diagnosing major cardiovascular diseases. Tempus ECG-AF (Tool B) is described as identifying patients at increased risk of developing AF, with a sensitivity of 31% and specificity of 92% for classifying patients who developed clinically recognized AF within one year.